Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology

Drug Profile

Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology

Alternative Names: Ag-D-CIK - Shenzhen Hornetcorn Biotechnology; Autologous dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn; Autologous tumour lysate-pulsed DCIK - Shenzhen Hornetcorn; DC activated CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK Biotherapy - Shenzhen Hornetcorn Biotechnology; DCIK - Shenzhen Hornetcorn Biotechnology; Dendritic and cytokine-induced killer cells - Shenzhen Hornetcorn; Dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn

Latest Information Update: 08 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shenzhen Hornetcorn Biotechnology
  • Developer Affiliated Tumor Hospital of Guangzhou Medical University; Shenzhen Hornetcorn Biotechnology
  • Class Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytokine induced killer cell inhibitors; Cytokine induced killer cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Gastric cancer; Hepatocellular carcinoma; Oesophageal cancer
  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 01 Feb 2016 Phase I/II clinical trials Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT02651441)
  • 05 Jan 2016 Shenzhen Hornetcorn Bio-technology Company plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in China (NCT02651441)
  • 01 Dec 2015 Phase-II clinical trials in Oesophageal cancer (Late-stage disease, Combination therapy) in China (IV) (NCT02644863)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top